1. The claim, and why it's usually too blunt
Every few months a column runs arguing that ADHD is a manufactured epidemic and that we're drugging a generation of restless kids into compliance. I get asked about it in the first visit all the time. Parents arrive already braced to feel guilty.
Here's the problem with the claim: it lumps "ADHD," "stimulants," and "pediatric psychiatric medication" into one rising line, then treats that line as proof of overprescribing. The data don't support that. When you pull the three big pediatric drug classes apart and lay each one next to its own diagnosis trend, they don't move together. They tell three different stories. Only one of them is an overprescribing story, and it isn't the ADHD one.
I spent a stretch of 2025 assembling a three-decade review of US pediatric prescribing for stimulants, antipsychotics, and SSRIs, cross-referenced against diagnosis-rate epidemiology. What follows is the patient-facing version of what that review found.
2. Stimulants rose, but they tracked diagnosis
Stimulant use in American children did climb. In children aged 6-14, it went from about 1.2% in 1987 to 4.1% by 1996 (Olfson 2002), and ADHD medication use in 6-11 year-olds rose from 4.8% in 1999-2002 to 6.2% in 2011-2014 (Hales 2018, the big NHANES population series).
So why isn't that overprescribing? Because diagnosis rose alongside it, and prescribing never overshot diagnosis. That's the key contrast. When a drug class is genuinely overprescribed, you see use racing past any plausible indication. Stimulants didn't do that. They stayed proportional to the diagnosed population, and actually ran a step behind it.
Olfson's own 2016 analysis put it plainly: the stimulant treatment rate for older children (4.5%) sits below the estimated community prevalence of ADHD (about 6.5%; Polanczyk 2007), a pattern the authors attribute to delays in treatment-seeking and undertreatment, not excess.
| Year | ADHD ever-diagnosed (4-17) | Currently medicated | Stimulant Rx (6-12) |
|---|---|---|---|
| 1996 | not yet tracked | — | ~4.1% (6-14, Olfson 2002) |
| 2007 | 9.5% | 4.8% | rising |
| 2011 | 11.0% | 6.1% | 4-6% across studies |
| 2014 | ~12% | rising | 6.2% (6-11, NHANES) |
Read the table across, not down. In every year where we can measure both, the diagnosed pool is larger than the treated pool. That is the signature of undertreatment.
3. The undertreatment gap is biggest where it matters most
Among children currently diagnosed with ADHD, roughly 70% are on medication. The other 30% aren't. And the gap widens with age. By late adolescence, around 14% of 15-17 year-olds carry an ADHD diagnosis but only about 6% are medicated (Visser 2014).
That's the worst possible place for a treatment gap. Late adolescence is exactly when the downstream harms of untreated ADHD concentrate: car crashes, first substance use, school dropout, early criminal-justice contact. The teenagers slipping off treatment aren't being over-served. They're being dropped right before the window where treatment does the most to change a trajectory.
For the full evidence on what that untreated stretch costs, see my companion review, Adverse Outcomes of Untreated ADHD, and on what changes when treatment is in place, ADHD Pharmacology & Natural Course.
4. Here's the actual overprescribing problem: antipsychotics
If you want a pediatric drug class that genuinely outran its indications, it's antipsychotics, not stimulants.
Antipsychotic use in children 6-11 doubled from 0.5% to 1.2% between 1999-2002 and 2011-2014 (Hales 2018). But the prescribing didn't follow the on-label diagnoses. Pediatric schizophrenia prevalence is under 0.5%. Yet in office-based data, about 94% of pediatric antipsychotic prescriptions had no FDA-approved indication (Olfson 2012).
The most telling number is about who's getting them. Among antipsychotic-treated children aged 1-6, the single most common diagnosis was ADHD (52.5%). Schizophrenia was 0.3% (Olfson 2015). These aren't being prescribed for psychosis. They're being prescribed for aggression and irritability in young children who often already have ADHD, frequently without an adequate stimulant trial first.
That last part is my own research. In a national MarketScan cohort of 187,563 youth with new ADHD diagnoses, my colleagues and I found that 2.6% were started on an antipsychotic within the year, and 47.9% of those had never received a stimulant trial first (Sultan, JAMA Network Open 2019). Antipsychotic-treated youth were far more likely to have recent self-harm or suicidal ideation (aOR 7.5), oppositional defiant disorder (aOR 4.4), and recent psychiatric hospitalization (aOR 7.9). When first-line ADHD pharmacology gets skipped, the next escalation tends to be a class with a much worse metabolic profile.
I've written about this problem in depth on two companion pages: Pediatric Antipsychotic Overuse and Pediatric Psychotropic Prescribing Patterns.
5. And a second gap: teen depression after the black-box
The third class rounds out the picture. After the 2004 FDA black-box warning on pediatric SSRI suicidality, adolescent SSRI use fell from 2.9% (1999-2002) to 2.0% (2011-2014) (Hales 2018). Over the same stretch, adolescent major depression diagnoses rose.
Prescribing moved opposite to need. That's the cleanest case of a regulatory intervention overshooting: depression climbing, treatment shrinking. It's the mirror image of the overmedication story everyone worries about, and it gets almost no airtime.
6. The 3.5-fold state gap that undercuts the "epidemic" framing
One number does more than any other to puncture the idea of a uniform ADHD epidemic: geography. In 2011, current ADHD prevalence ranged from 4.2% in Nevada to 14.8% in Kentucky (Visser 2014). Methylphenidate prescription rates have varied roughly 10-fold from one county to the next (Zito 2000).
No biological story explains a 3.5-fold difference in a neurodevelopmental condition across state lines. What explains it is practice: how local physicians diagnose, how readily parents seek help, how schools handle attention problems, what insurance covers. Administrative "ADHD prevalence" is part real prevalence and part practice pattern. That cuts against crude overdiagnosis claims and crude underdiagnosis claims alike. It means the right rate is local, and the national average hides a lot.
Across three careful decades of worldwide study, true ADHD prevalence has stayed near 5-7% (Polanczyk 2014). The diagnosis line moved more than the disorder did, but it moved toward better recognition, not toward invention.
7. What I actually tell parents
"Overmedicated" is the wrong frame for your kid's ADHD. At the population level, diagnosed ADHD is undertreated, not overtreated, and the undertreatment is worst in the teenage years when the stakes are highest. The stimulant your pediatrician is being cautious about is the best-studied, best-monitored drug we have for this condition.
The prescribing I'd push back on is different. Be skeptical of an antipsychotic for a young child who hasn't had a proper stimulant trial. Be skeptical of stacking medications instead of optimizing one. And know that after the 2004 SSRI warning, a lot of genuinely depressed teenagers stopped getting treated at all.
None of this means every diagnosis is right or every prescription is needed. Individual overprescribing is real, and so is sloppy diagnosis. But the question worth asking in the room isn't "are we doing too much?" It's "are we treating the actual ADHD adequately, and are we escalating to riskier drugs too quickly when we should be getting the first-line treatment right?"
— Ryan S. Sultan, MD
Read the companion reviews
The two halves of the trajectory question: what untreated ADHD costs, and what treatment changes.
Adverse Outcomes of Untreated ADHD → ADHD Pharmacology & Natural Course →8. Frequently asked questions
Is ADHD overdiagnosed?
Diagnosis rates rose (about 11% ever-diagnosed in US children 4-17 by 2011), but most of that reflects better recognition of real impairment. Global prevalence has stayed near 5-7% across three decades (Polanczyk 2014). The strongest counter to a simple overdiagnosis story is the 3.5-fold variation between US states, which points to practice patterns rather than a uniform epidemic.
Are children overmedicated for ADHD with stimulants?
On average, no. About 4.5% of children 6-12 receive a stimulant against a community ADHD prevalence near 6.5% (Olfson 2016; Polanczyk 2007). Only about 70% of diagnosed children are medicated, and in late adolescence the gap is roughly 14% diagnosed versus 6% treated (Visser 2014). That's undertreatment at the population level.
Have ADHD diagnoses actually increased?
Yes. Stimulant use in children 6-14 went from about 1.2% (1987) to 4.1% (1996), and 6-11 ADHD medication use rose from 4.8% to 6.2% between 1999-2002 and 2011-2014. Diagnosis rose with it, and prescribing tracked diagnosis rather than overshooting it.
Which psychiatric medications are actually overprescribed in children?
Antipsychotics. About 94% of pediatric antipsychotic use is off-label (Olfson 2012), use in 6-11 year-olds doubled to 1.2% (Hales 2018), and the most common diagnosis among antipsychotic-treated 1-6 year-olds is ADHD, not psychosis, with schizophrenia at 0.3% (Olfson 2015).
Why do ADHD rates vary so much by state?
Because administrative prevalence reflects practice as much as biology. Current ADHD prevalence ranged from 4.2% (Nevada) to 14.8% (Kentucky) in 2011, and county methylphenidate rates have varied roughly 10-fold (Visser 2014; Zito 2000).
Did the FDA black-box warning cause undertreatment of teen depression?
The data point that way. Adolescent SSRI use fell from 2.9% to 2.0% after the 2004 warning even as depression diagnoses rose (Hales 2018), prescribing moving opposite to need.
So is the "kids are overmedicated" narrative wrong?
It's mostly aimed at the wrong target. The worry attaches to stimulants and ADHD, where the reality is undertreatment relative to diagnosis. The real concerns are off-label antipsychotic use in young children, rising polypharmacy, and SSRI undertreatment of adolescent depression.
References
- Olfson M, King M, Schoenbaum M. Stimulant Treatment of Young People in the United States. J Child Adolesc Psychopharmacol. 2016;26(6):520-526.
- Olfson M, King M, Schoenbaum M. Treatment of Young People With Antipsychotic Medications in the United States. JAMA Psychiatry. 2015;72(9):867-874.
- Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National Trends in the Office-Based Treatment of Children, Adolescents, and Adults With Antipsychotics. Arch Gen Psychiatry. 2012;69(12):1247-1256.
- Olfson M, Marcus SC, Weissman MM, Jensen PS. National Trends in the Use of Psychotropic Medications by Children. J Am Acad Child Adolesc Psychiatry. 2002;41(5):514-521.
- Hales CM, Kit BK, Gu Q, Ogden CL. Trends in Prescription Medication Use Among Children and Adolescents-United States, 1999-2014. JAMA. 2018;319(19):2009-2020.
- Visser SN, Danielson ML, Bitsko RH, et al. Trends in the Parent-report of Health Care Provider-Diagnosed and Medicated ADHD: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34-46.
- Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the Prescribing of Psychotropic Medications to Preschoolers. JAMA. 2000;283(8):1025-1030.
- Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434-442.
- Sultan RS, Wang S, Crystal S, Olfson M. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder. JAMA Network Open. 2019;2(7):e197850. doi:10.1001/jamanetworkopen.2019.7850
- Sultan RS, Correll CU, Schoenbaum M, King M, Walkup JT, Olfson M. National Patterns of Commonly Prescribed Psychotropic Medications to Young People. J Child Adolesc Psychopharmacol. 2018;28(3):158-165. doi:10.1089/cap.2017.0077
- Crystal S, Mackie T, Fenton MC, et al. Rapid Growth Of Antipsychotic Prescriptions For Children Who Are Publicly Insured Has Ceased, But Concerns Remain. Health Aff. 2016;35(6):974-982.
Citations link to the primary literature where a public identifier is available. Additional Sultan Lab publications are indexed via PubMed and Google Scholar.
Questions about an ADHD diagnosis or medication?
Dr. Sultan provides ADHD evaluation and pharmacologic management for children, adolescents, and adults in New York City.
Request ConsultationAbout Dr. Ryan Sultan
Dr. Ryan Sultan is Assistant Professor of Clinical Psychiatry at Columbia University Irving Medical Center, Director of the Sultan Lab for Mental Health Informatics, and a double board-certified Adult and Child/Adolescent psychiatrist. A through-line of his research is pediatric psychopharmacology epidemiology: how psychiatric medications are actually prescribed to young people, and how that prescribing lines up (or doesn't) with the underlying diagnoses.
His 2019 JAMA Network Open study on antipsychotic prescribing in youth with ADHD has been cited 440+ times. His 2018 J Child Adolesc Psychopharmacol paper mapped national psychotropic prescribing patterns by age. His 2025 JAMA Psychiatry analysis with Saunders and Veenstra-VanderWeele documented how ADHD medication changes real-world outcomes.
Work With Dr. Sultan
Dr. Ryan S. Sultan, MD evaluates and treats ADHD across the lifespan — children, adolescents, and adults — at Integrative Psych in Chelsea, Manhattan. Subspecialty expertise in pediatric psychopharmacology and prescribing to children. Consultations cover initial diagnostic evaluation, medication optimization, and second opinions on complex cases.
What sets Dr. Sultan's practice apart: Double board certification in Adult Psychiatry and Child & Adolescent Psychiatry. Active NIH-funded ADHD research at Columbia. 440+ research citations. Author of the 2019 JAMA Network Open study (Sultan, Wang, Crystal, Olfson) on antipsychotic prescribing in youth ADHD, and the 2025 JAMA Psychiatry analysis (Sultan, Saunders, Veenstra-VanderWeele) of real-world functional outcomes.